American Association for Cancer Research
15357163mct141055t-sup-142280_1_supp_3001257_np6c63.docx (14.91 kB)

Supplemental figure legends from Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression

Download (14.91 kB)
journal contribution
posted on 2023-04-03, 14:20 authored by Zhiqun Shang, Yanjun Li, Minghao Zhang, Jing Tian, Ruifa Han, Chih-Rong Shyr, Edward Messing, Shuyuan Yeh, Yuanjie Niu, Chawnshang Chang

Supplemental figure 1 ASC-J9® degraded androgen receptor expression in bladder cancer cells.Supplemental figure 2 HF or ASC-J9® induced THP-1 cell differentiating to M1 macrophage



Recent studies suggest that the androgen receptor (AR) might play important roles in influencing bladder cancer progression, yet its clinical application remains unclear. Here, we developed a new combined therapy with Bacillus Calmette–Guérin (BCG) and the AR degradation enhancer ASC-J9 or antiandrogen hydroxyflutamide (HF) to better suppress bladder cancer progression. Mechanism dissection revealed that ASC-J9 treatment enhanced BCG efficacy to suppress bladder cancer cell proliferation via increasing the recruitment of monocytes/macrophages that involved the promotion of BCG attachment/internalization to the bladder cancer cells through increased integrin-α5β1 expression and IL6 release. Such consequences might then enhance BCG-induced bladder cancer cell death via increased TNFα release. Interestingly, we also found that ASC-J9 treatment could directly promote BCG-induced HMGB1 release to enhance the BCG cytotoxic effects for suppression of bladder cancer cell growth. In vivo approaches also concluded that ASC-J9 could enhance the efficacy of BCG to better suppress bladder cancer progression in BBN-induced bladder cancer mouse models. Together, these results suggest that the newly developed therapy combining BCG plus ASC-J9 may become a novel therapy to better suppress bladder cancer progress. Mol Cancer Ther; 14(11); 2586–94. ©2015 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager